Vera Therapeutics Files 8-K for 'Other Event' on Jan 29

TL;DR

**Vera Therapeutics filed an 8-K for an undisclosed 'Other Event' on Jan 29, watch for details.**

AI Summary

Vera Therapeutics, Inc. filed an 8-K on January 30, 2024, reporting an 'Other Event' that occurred on January 29, 2024. This filing indicates a routine update or disclosure of an event that the company deems important enough to report immediately, but the specific details of the event are not provided within this particular filing. For investors, this means Vera Therapeutics is adhering to SEC reporting requirements, but the actual impact of the 'Other Event' cannot be assessed without further information, which would typically be found in an exhibit or a more detailed description within the filing itself, which is absent here.

Why It Matters

This filing signals that Vera Therapeutics had an event on January 29, 2024, that it considers material enough to report, but without details, investors cannot determine its impact on the company's operations or stock price.

Risk Assessment

Risk Level: medium — The risk is medium because an 'Other Event' without specific details creates uncertainty for investors regarding its potential positive or negative impact.

Analyst Insight

A smart investor would monitor subsequent filings or company announcements from Vera Therapeutics for specific details regarding the 'Other Event' reported on January 29, 2024, before making any investment decisions.

Key Players & Entities

• Vera Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 29, 2024 (date) — date of the earliest event reported
• January 30, 2024 (date) — date the 8-K was filed
• 001-40407 (other) — Commission File Number
• Vera (company) — trading symbol on Nasdaq
• The Nasdaq Stock Market LLC (company) — exchange where Class A common stock is registered

FAQ

Key Financial Figures

• $0.001 — which registered Class A common stock, $0.001 par value per share VERA The Nasdaq
• $31.00 — price to the public in the offering was $31.00 per share. The gross proceeds to the Co
• $250.0 m — from the offering will be approximately $250.0 million, before deducting underwriting di

Filing Documents

• d761446d8k.htm (8-K) — 31KB
• d761446dex11.htm (EX-1.1) — 197KB
• d761446dex51.htm (EX-5.1) — 9KB
• g761446g32u83.jpg (GRAPHIC) — 3KB
• 0001193125-24-019496.txt ( ) — 423KB
• vera-20240129.xsd (EX-101.SCH) — 3KB
• vera-20240129_lab.xml (EX-101.LAB) — 18KB
• vera-20240129_pre.xml (EX-101.PRE) — 11KB
• d761446d8k_htm.xml (XML) — 4KB

Forward Looking Statements

Forward Looking Statements Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements about the Company's expectations with respect to the completion of the offering and the expected gross proceeds from the offering. Words such as "expect", "may," and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. For such statements, the Company claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from the Company's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, and the impact of macroeconomic and geopolitical events. Additional factors that could cause actual results to differ materially from those stated or implied by the Company's forward-looking statements are disclosed in the Company's filings with the SEC, including in the section captioned "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequently filed Quarter Reports on Form 10-Q and the prospectus supplement relating to the offering. These forward-looking statements represent the Company's judgment as of the time of this report. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law. Item9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C., dated January 29, 2024. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Dated: January 30, 2024 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR